BRPI0413363A - formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase - Google Patents
formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutaseInfo
- Publication number
- BRPI0413363A BRPI0413363A BRPI0413363-3A BRPI0413363A BRPI0413363A BR PI0413363 A BRPI0413363 A BR PI0413363A BR PI0413363 A BRPI0413363 A BR PI0413363A BR PI0413363 A BRPI0413363 A BR PI0413363A
- Authority
- BR
- Brazil
- Prior art keywords
- hmg
- inhibitors
- transfer protein
- ester transfer
- coa reductase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
"FORMAS DE DOSAGEM FORNECENDO LIBERAçãO CONTROLADA DE INIBIDORES DE PROTEìNA DE TRANSFERêNCIA DE éSTERES DE COLESTERILA E LIBERAçãO IMEDIATA DE INIBIDORES DE HMG-CoA REDUTASE". Uma forma de dosagem que compreende um inibidor da proteína de transferência de ésteres de colesterila em uma forma com solubilidade melhorada e um inibidor de HMG-CoA redutase, em que a forma de dosagem proporciona liberação imediata do inibidor de HMG-CoA redutase e liberação controlada do inibidor da proteína de transferência de ésteres de colesterila.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49240703P | 2003-08-04 | 2003-08-04 | |
PCT/IB2004/002457 WO2005011634A1 (en) | 2003-08-04 | 2004-07-21 | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413363A true BRPI0413363A (pt) | 2006-10-10 |
Family
ID=34115617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413363-3A BRPI0413363A (pt) | 2003-08-04 | 2004-07-21 | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase |
Country Status (16)
Country | Link |
---|---|
US (1) | US20050038007A1 (pt) |
EP (1) | EP1653926A1 (pt) |
JP (1) | JP2007501217A (pt) |
KR (1) | KR20060033033A (pt) |
CN (2) | CN1863511A (pt) |
AR (1) | AR045203A1 (pt) |
AU (1) | AU2004261058A1 (pt) |
BR (1) | BRPI0413363A (pt) |
CA (1) | CA2534371A1 (pt) |
IL (1) | IL172875A0 (pt) |
MX (1) | MXPA06001506A (pt) |
NO (1) | NO20061072L (pt) |
RU (1) | RU2006102981A (pt) |
TW (1) | TW200517145A (pt) |
WO (1) | WO2005011634A1 (pt) |
ZA (2) | ZA200600179B (pt) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
US20050196439A1 (en) * | 2003-10-24 | 2005-09-08 | J. Rettenmaier & Soehne Gmbh + Co. Kg | Process for co-spray drying agents with dry silicified MCC |
DK1848430T3 (da) | 2004-12-31 | 2017-11-06 | Dr Reddys Laboratories Ltd | Nye benzylamin-derivativer som cetp-inhibitors |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
CA2601762A1 (en) * | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
CN1331476C (zh) * | 2005-07-05 | 2007-08-15 | 凌沛学 | 一种辅酶a舌下含片及其制备方法 |
WO2007067593A2 (en) * | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Self-emulsifyng formulations of cetp inhibitors |
KR100742571B1 (ko) * | 2006-03-02 | 2007-07-25 | 충남대학교산학협력단 | 초임계유체 공정을 이용한 무정형 아토르바스타틴 칼슘염및 그 제조방법 |
EP2007346A1 (en) * | 2006-05-08 | 2008-12-31 | McNeil-PPC, Inc. | Osmotic dosage form |
WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
KR100885029B1 (ko) * | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
WO2008115529A1 (en) * | 2007-03-20 | 2008-09-25 | Reliant Pharmaceuticals, Inc. | Compositions comprising omega-3 fatty acids and cetp inhibitors |
WO2008135855A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
TW201016761A (en) * | 2008-10-30 | 2010-05-01 | Univ Nat Taiwan | Microporous film and preparation and use thereof |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
HUE048542T2 (hu) | 2009-06-16 | 2020-08-28 | Pfizer | Apixaban adagolási formái |
WO2011006066A1 (en) | 2009-07-10 | 2011-01-13 | Ironwood Pharmaceuticals, Inc. | Cb receptor agonists |
EP2473515A4 (en) | 2009-09-04 | 2013-11-27 | Univ Toledo | METHODS OF MAKING OPTICALLY PURE BETA-LACTONES FROM ALDEHYDES AND COMPOSITIONS OBTAINED THEREFROM |
BR112012017756A2 (pt) | 2009-12-23 | 2016-04-19 | Ironwood Pharmaceuticals Inc | moduladores crth2 |
WO2011100324A1 (en) | 2010-02-09 | 2011-08-18 | Ironwood Pharmaceuticals Inc. | Cannabinoid receptor agonists |
US20130178453A1 (en) | 2010-02-09 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Agonists |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
MX2012015252A (es) | 2010-06-30 | 2013-05-30 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc. |
WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
JP5982283B2 (ja) * | 2010-07-29 | 2016-08-31 | 田辺工業株式会社 | 減圧噴霧乾燥方法及び減圧噴霧乾燥装置 |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
KR101579659B1 (ko) * | 2010-11-04 | 2015-12-22 | 에프. 호프만-라 로슈 아게 | S-[2-([[1-(2-에틸부틸)-사이클로헥실]-카본일]아미노)페닐]2-메틸프로판티오에이트 및 크로스카멜로스 나트륨을 포함하는 조성물 |
RU2016101964A (ru) | 2010-11-09 | 2018-11-21 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ sGC |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物 |
WO2013046045A1 (en) | 2011-09-27 | 2013-04-04 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
CA2861804C (en) | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators |
WO2013155422A1 (en) | 2012-04-12 | 2013-10-17 | Ironwood Pharmaceuticals, Inc. | Methods of treating alopecia and acne |
JP2015515498A (ja) * | 2012-04-30 | 2015-05-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規製剤 |
US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
EP2919765A2 (en) * | 2012-11-19 | 2015-09-23 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
KR101986683B1 (ko) * | 2012-12-13 | 2019-06-10 | 한미약품 주식회사 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
RU2015128794A (ru) * | 2012-12-20 | 2017-01-25 | КАШИВ ФАРМА, ЭлЭлСи | Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность |
WO2014128564A2 (en) * | 2013-02-21 | 2014-08-28 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
EP3998260B1 (en) | 2013-03-15 | 2023-11-01 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
EA032028B1 (ru) | 2013-12-11 | 2019-03-29 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ рГЦ |
MX2016009056A (es) * | 2014-01-09 | 2017-01-23 | Verastem Inc | Composiciones y metodos para tratamiento de crecimiento celular anormal. |
CN112755032A (zh) * | 2014-08-28 | 2021-05-07 | 狄智玛制药私人有限公司 | 包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合 |
US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US20170291889A1 (en) | 2014-09-17 | 2017-10-12 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
CN107406421A (zh) | 2014-09-17 | 2017-11-28 | 铁木医药有限公司 | sGC刺激物 |
PT3507291T (pt) | 2016-09-02 | 2021-08-30 | Cyclerion Therapeutics Inc | Estimulantes de sgc bicíclicos fundidos |
CA3042713A1 (en) | 2016-11-08 | 2018-05-17 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
IL266275B2 (en) | 2016-11-08 | 2023-12-01 | Cyclerion Therapeutics Inc | Treatment of CNS diseases by SGC stimulators |
CN107019927A (zh) * | 2017-04-18 | 2017-08-08 | 成都绿林科技有限公司 | 用于药品快速干燥的干燥机 |
CN109663373A (zh) * | 2018-12-26 | 2019-04-23 | 无锡市林洲干燥设备有限公司 | 甲维盐闭式循环喷雾干燥系统 |
CN110773079B (zh) * | 2019-11-18 | 2022-03-01 | 江苏博迁新材料股份有限公司 | 一种超声喷雾法制备超细粉球的方法 |
CN115724771A (zh) * | 2021-08-30 | 2023-03-03 | 中国科学院过程工程研究所 | 一种用于制备n,n’-二苯基脲的装置系统及制备n,n’-二苯基脲的工艺 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US35125A (en) * | 1862-04-29 | Improvement in spring-balances | ||
US10325A (en) * | 1853-12-20 | Improvement in manure crushers and sowers | ||
CA2150372C (en) * | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
PT828495E (pt) * | 1995-06-01 | 2003-01-31 | Searle & Co | Dispersoes solidas estabilizadas de misoprostol |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
AU752673B2 (en) * | 1997-07-31 | 2002-09-26 | Abbott Laboratories | Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6462091B1 (en) * | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
DE60039802D1 (de) * | 1999-02-10 | 2008-09-25 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung |
ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
IL154348A0 (en) * | 2000-08-15 | 2003-09-17 | Pfizer Prod Inc | Therapeutic combination of a cetp inhibitor and atorvastatin |
EP1404300B1 (en) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
MXPA03011933A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados. |
-
2004
- 2004-07-21 KR KR1020067002353A patent/KR20060033033A/ko not_active Application Discontinuation
- 2004-07-21 RU RU2006102981/15A patent/RU2006102981A/ru not_active Application Discontinuation
- 2004-07-21 WO PCT/IB2004/002457 patent/WO2005011634A1/en active Application Filing
- 2004-07-21 EP EP04744109A patent/EP1653926A1/en not_active Withdrawn
- 2004-07-21 CN CNA2004800290032A patent/CN1863511A/zh active Pending
- 2004-07-21 BR BRPI0413363-3A patent/BRPI0413363A/pt not_active IP Right Cessation
- 2004-07-21 JP JP2006522426A patent/JP2007501217A/ja active Pending
- 2004-07-21 MX MXPA06001506A patent/MXPA06001506A/es unknown
- 2004-07-21 CA CA002534371A patent/CA2534371A1/en not_active Abandoned
- 2004-07-21 AU AU2004261058A patent/AU2004261058A1/en not_active Abandoned
- 2004-07-27 CN CNA2004800218379A patent/CN1870978A/zh active Pending
- 2004-07-30 US US10/903,433 patent/US20050038007A1/en not_active Abandoned
- 2004-08-03 TW TW093123237A patent/TW200517145A/zh unknown
- 2004-08-03 AR ARP040102760A patent/AR045203A1/es not_active Application Discontinuation
-
2005
- 2005-12-28 IL IL172875A patent/IL172875A0/en unknown
-
2006
- 2006-01-06 ZA ZA200600179A patent/ZA200600179B/en unknown
- 2006-01-30 ZA ZA200600853A patent/ZA200600853B/en unknown
- 2006-03-06 NO NO20061072A patent/NO20061072L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007501217A (ja) | 2007-01-25 |
KR20060033033A (ko) | 2006-04-18 |
AU2004261058A1 (en) | 2005-02-10 |
CA2534371A1 (en) | 2005-02-10 |
MXPA06001506A (es) | 2006-05-15 |
CN1863511A (zh) | 2006-11-15 |
ZA200600179B (en) | 2007-02-28 |
EP1653926A1 (en) | 2006-05-10 |
NO20061072L (no) | 2006-05-04 |
ZA200600853B (en) | 2007-04-25 |
TW200517145A (en) | 2005-06-01 |
US20050038007A1 (en) | 2005-02-17 |
IL172875A0 (en) | 2006-06-11 |
WO2005011634A1 (en) | 2005-02-10 |
RU2006102981A (ru) | 2007-09-20 |
AR045203A1 (es) | 2005-10-19 |
CN1870978A (zh) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413363A (pt) | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase | |
TW200638950A (en) | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | |
MY143407A (en) | Indazole derivatives as inhibitors of hormone sensitive lipase | |
GT200300023A (es) | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo | |
UY27639A1 (es) | Composiciones farmacéuticas de inhibidores de la proteína de transferencia de ésteres de colesterilo | |
UY26864A1 (es) | Composiciones farmaceúticas de inhibidores de la proteína de transferencia de colesteril éster | |
MX2009010284A (es) | Inhibidores de la tirosina-cinasa de bruton. | |
DK1223918T3 (da) | Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor | |
BR0317715A (pt) | Composições e processos de uso de collajolie | |
CY1108725T1 (el) | Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer | |
HN2003000227A (es) | Inhibidores de quinasas | |
TW200728285A (en) | Diacylindazole derivatives as inhibitors of lipases and phospholipases | |
NO20054369L (no) | Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse | |
DE60202452D1 (de) | Pyridazinonaldose reductase inhibitoren | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
CY1109523T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv | |
ECSP055888A (es) | Derivados de aril-quinazolin/aril-2-amino-fenil metanona que promueven la liberación de la hormona paratiroides. | |
HN2001000146A (es) | Derivados de pirazol | |
EP1740183B8 (en) | Novel use for pde5 inhibitors | |
BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
BR0317593A (pt) | Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase | |
NO20044898L (no) | Nye etonogestrel estere | |
HRP20090513T1 (en) | S-mirtazapine for the treatment of hot flush | |
HUP0401854A2 (hu) | COX-2 inhibitorokat és aszpirint tartalmazó kombinációk | |
MY146444A (en) | Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A,6A E 7A ANUIDADE(S) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |